Your browser doesn't support javascript.
loading
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
Rataj, Felicitas; Jacobi, Severin J; Stoiber, Stefan; Asang, Florian; Ogonek, Justyna; Tokarew, Nicholas; Cadilha, Bruno L; van Puijenbroek, Erwin; Heise, Constanze; Duewell, Peter; Endres, Stefan; Klein, Christian; Kobold, Sebastian.
Afiliación
  • Rataj F; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany.
  • Jacobi SJ; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany.
  • Stoiber S; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany.
  • Asang F; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany.
  • Ogonek J; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany.
  • Tokarew N; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany.
  • Cadilha BL; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany.
  • van Puijenbroek E; Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Heise C; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany.
  • Duewell P; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany.
  • Endres S; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany.
  • Klein C; Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Kobold S; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU Munich (Member of the German Center for Lung Research (DZL), LMU Munich, Germany. Sebastian.kobold@med.uni-muenchen.de.
Br J Cancer ; 120(1): 79-87, 2019 01.
Article en En | MEDLINE | ID: mdl-30429531
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Receptores Quiméricos de Antígenos / Inmunoterapia / Neoplasias Límite: Animals / Humans Idioma: En Revista: Br J Cancer Año: 2019 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Receptores Quiméricos de Antígenos / Inmunoterapia / Neoplasias Límite: Animals / Humans Idioma: En Revista: Br J Cancer Año: 2019 Tipo del documento: Article País de afiliación: Alemania